Semantic search
| Topic | Outcome name | Outcome specification | |
|---|---|---|---|
| Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies | Cannabinoids | Pain Pain Pain Sleep Additional medication Quality of life | Change in NRS value for moderate pain Median improvement in pain with NRS in % Change in NRS value for the worst pain Extent of sleep disturbance (assessed with NRS) General intake, appropriate opioid intake for breakthrough pain and total opioid intake per day in morphine equivalents Specification NRS: constipation NRS |
| Goossens et al. (2016): Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial | Selenium | RFS (Recurrence-Free Survival) PFS (Progression-Free Survival) Selenium level | NA NA Measured at baseline and after 3 years |
| Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial | Cannabinoids | CINV (Chemotherapy-Induced Nausea and Vomiting) CINV (Chemotherapy-Induced Nausea and Vomiting) Quality of life Toxicity | Complete response, no vomiting or emergency medication 0-120h of chemotherapy Self-reported "complete response" ("no vomiting", "no clinically significant nausea", defined as nausea <2 on a 10-point scale, and "no use of emergency medication") during the acute (0-24 h), delayed (24-120 h) and general phase (0-120 h) of chemotherapy with diary day -1 to 6 of each cycle) Quality of life (nausea & vomiting scales) at baseline, day -1, end of treatment Self-developed measurement instrument: structured checklist of cannabinoid-specific adverse events |
| Hejazi et al. (2013): A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer | Curcumin | Quality of life | With EORTC QLQ-PR25 |
| Hejazi et al. (2016): Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study | Curcumin | PFS (Progression-Free Survival) | During 1 year |